Maintaining/Regrown on Fin but losing ground on Dut?
    Finasteride/Dutasteride 4/1/2026

    From the encyclopedia
    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    Dutasteride →

    Heavy duty finasteride that comes with higher risks

    Minoxidil →

    An essential vasodilator with some anti-androgenic effects

    At a glance
    In this treatment experience post, the primary subjects mentioned are
    💊 Finasteride (oral) 1mg 1x daily 15 months
    💊 Dutasteride (oral) 0.5mg 1x daily 15 months
    💊 Minoxidil (oral) 7.5mg
    the tone is 😞 negative with no growth results.

    Other terms

    Switching from finasteride to dutasteride led to hairline regression and scalp issues for some users, prompting a return to finasteride. Users reported better maintenance and regrowth with finasteride compared to dutasteride, despite using oral minoxidil throughout.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

    Related Research

    6 / 6 results
      Dermatosis Associated with Menopause

      research Dermatosis associated with menopause

      10 citations , January 2014 in “Journal of Mid-life Health”
      This article reviews dermatological problems associated with estrogen deficiency in menopausal women and highlights the importance of dermatologist and gynecologist collaboration, but reports no new clinical results.
      Overactive Bladder in Men: Finasteride for Androgenetic Alopecia

      research Overactive bladder in men

      1 citations , January 2009 in “CRC Press eBooks”
      This chapter discusses the increasing prevalence of overactive bladder in aging men, examining potential causes and treatment options, without reporting new clinical results.
      Hair Physiology: Hair Growth, Alopecia, Scalp Treatment, Etc.

      research Hair Physiology (Hair Growth, Alopecia, Scalp Treatment, etc.)

      1 citations , January 2017 in “Elsevier eBooks”
      This article reviews various hair growth and hair loss treatments, noting limited new developments since FDA-approved drugs but highlights recent cosmetic surgery and potential cell-based therapies; it reports no original findings.